Sigumir is a short-chain peptide bioregulator developed at the St. Petersburg Institute of Bioregulation and Gerontology. It’s part of the Khavinson peptide family, targeting cartilage and joint tissue.
What Is Sigumir?
- Type: Synthetic tripeptide bioregulator
- Target Tissue: Cartilage, joints, connective tissue
- Origin: Russian bioregulatory peptide research
- Sequence: Glu-Asp-Leu (Glutamic acid - Aspartic acid - Leucine)
Mechanism of Action
Sigumir works through peptide bioregulation — binding to specific DNA sequences to modulate gene expression in cartilage cells (chondrocytes).
Proposed effects:
- Stimulates chondrocyte activity and matrix production
- Supports collagen synthesis in cartilage
- May slow age-related cartilage degeneration
- Regulatory effect on joint tissue metabolism
Research Status
Most research comes from Russian institutions:
- Chondrocyte studies: In vitro evidence of increased cartilage matrix synthesis
- Animal models: Improved cartilage integrity markers in aging animals
- Clinical observations: Used in Russian clinical practice for osteoarthritis
- Western studies: Limited; not widely studied outside Russia
Evidence level: Preliminary. Mostly Russian literature, limited peer review in Western journals.
Dosing Protocol
Oral Form (Capsules)
| Parameter | Standard Protocol |
|---|---|
| Dose | 1-2 capsules (10-20 mg) |
| Frequency | 1-2x daily |
| Timing | Before meals |
| Duration | 10-30 days |
| Cycling | Repeat after 3-6 months |
Injectable Form
Less common. When used:
- 10-20 mcg subcutaneous
- Once daily for 10-20 days
- Near affected joints or systemic
Who Uses Sigumir?
- Osteoarthritis patients: primary use case
- Athletes: joint preservation, recovery support
- Aging population: preventive cartilage maintenance
- Post-injury: supporting joint recovery
What to Expect
Weeks 1-2
- Minimal immediate effects
- Bioregulators work gradually
Weeks 2-4
- Some users report reduced joint stiffness
- Possible reduction in discomfort during movement
After Full Course
- Improved joint comfort reported
- Effects may persist for months after stopping (bioregulatory effects)
- Benefits typically build with repeated courses
Side Effects
Generally well-tolerated:
- Rare reports of mild GI discomfort
- No significant adverse effects in available literature
- No known drug interactions (limited data)
Stacking
Often combined with other joint-support compounds:
- BPC-157: different mechanism, may be synergistic
- TB-500: tissue repair support
- Collagen peptides: structural support
- Chondroitin/Glucosamine: traditional joint support
Sourcing
- Primarily available from Russian suppliers
- Some European peptide companies stock it
- Quality varies; look for reputable sources with third-party testing
The Honest Take
Sigumir is intriguing but under-researched by Western standards. Russian bioregulatory peptide research is extensive but not always accessible or peer-reviewed in English. If you’re dealing with joint issues and have tried standard interventions, it may be worth exploring, but don’t expect miracles from compounds with limited clinical validation.
For more established joint peptides, see BPC-157 for Knee Pain. For the healing stack, see BPC-157 + TB-500.